Company
Glyphic Bio
Advancing life science discovery with massively parallel, single-molecule proteome sequencing
Also known as Glyphic, Glyphic Biotechnologies, Glyphic Biotechnologies, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Berkeley, CA, United States
- Founded
- 2021
- Legal name
- Glyphic Biotechnologies, Inc.
- glyphic.bio (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Glyphic Biotechnologies, Inc. is developing the first truly de novo high-throughput proteome sequencing technology capable of discriminating all 20 AAs and PTMs accurately with single molecule sensitivity.
Funding snapshot
- Total raised
- $33.2MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $33.2M2024-02-07
Funding rounds
- Round, 2024
- $33.2M2024-02-07, SEC form D sold, 37 investors
Products
- Web
- ProSE™
- Hardware
- Protein Sequencing by Expansion (ProSE™)
- Web
- Protein Sequencing by Expansion (ProSE™)
Loading relationship preview